BMS’s Mezigdomide Scores In Second-Line Myeloma

 
• By Alaric DeArment
  
BMS announced results of the Phase III SUCCESSOR-2 trial of mezigdomide combined with Amgen's Kyprolis and dexamethasone in relapsed/refractory multiple myeloma. (Alaric DeArment)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D